LIVIVO - Search results -

Search results

Result 1 - 10 of total 49

Search options

Article: It Is Not Always an Ectopic or Heterotopic Pregnancy.

Kamal Mohamed, Ahmed / Awadalla, Sakher / Nawaz, Ali

2023 Volume 15, Issue 4, Page(s) e37083

Abstract: Uterine rupture is a life-threatening peripartum complication. Spontaneous uterine rupture in early pregnancy is very rare. The diagnosis of uterine rupture should be considered when a pregnant patient presents with an acute abdomen because its clinical ... ...

Abstract	Uterine rupture is a life-threatening peripartum complication. Spontaneous uterine rupture in early pregnancy is very rare. The diagnosis of uterine rupture should be considered when a pregnant patient presents with an acute abdomen because its clinical signs in early pregnancy are non-specific and the differentiation with other acute abdominal emergencies is challenging. Here, we present a case of acute abdominal pain. The patient was a 14-week pregnant 39-year-old female (gravida 4, para 2+1) with a history of two lower-segment cesarean sections. Our preoperative diagnosis was either heterotopic pregnancy or acute abdomen. Emergency laparotomy confirmed the presence of a spontaneous uterine rupture.
Language	English
Publishing date	2023-04-03
Publishing country	United States
Document type	Case Reports
ZDB-ID	2747273-5
ISSN	2168-8184
ISSN	2168-8184
DOI	10.7759/cureus.37083
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Oseltamivir pharmacology in young children: a commentary.

Kamal, Mohamed A

Infectious disorders drug targets

2013 Volume 13, Issue 1, Page(s) 2–5

Abstract: Oseltamivir is listed by the World Health Organization as an essential drug for the treatment and prophylaxis of both seasonal and pandemic influenza. Since influenza mortality is highest in neonates and infants, optimal dosing of oseltamivir in this ... ...

Abstract	Oseltamivir is listed by the World Health Organization as an essential drug for the treatment and prophylaxis of both seasonal and pandemic influenza. Since influenza mortality is highest in neonates and infants, optimal dosing of oseltamivir in this high risk population is of utmost public health concern. To date, only two major clinical trials have been conducted investigating oselatmivir exposure and exposure/response in neonates and infants. The first study was a prospective, open label pharmacokinetic/pharmacodynamic and safety evaluation of oseltamivir in a total of 87 young children less than 2 years of age and was conducted by the National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Antiviral Study Group (CASG). The second Roche sponsored study was also an open label, prospective, pharmacokinetic/ pharmacodynamic and safety evaluation of oseltamivir in the treatment of 65 children less than 12 months of age. A recent supplemental new drug application (sNDA) was submitted to the Food and Drug Administration (FDA) on the basis of these two studies which resulted in oseltamivir becoming the first and so far only neuraminidase inhibitor to gain FDA approval for treatment of influenza in neonates and infants less than 1 year of age. The two review articles in this volume discuss the complex pharmacokinetics of oseltamivir and its active metabolite oseltamivir carboxylate from different perspectives while attempting to contrast and critique different literature views of the optimal dose in neonates, infants and young children. The articles also offer suggestions to generate more robust pediatric PKPD data and mend current gaps in knowledge.
MeSH term(s)	Antiviral Agents/adverse effects ; Antiviral Agents/pharmacokinetics ; Antiviral Agents/therapeutic use ; Child, Preschool ; Enzyme Inhibitors/adverse effects ; Enzyme Inhibitors/pharmacokinetics ; Enzyme Inhibitors/therapeutic use ; Humans ; Infant ; Infant, Newborn ; Influenza, Human/drug therapy ; Neuraminidase/antagonists & inhibitors ; Oseltamivir/adverse effects ; Oseltamivir/pharmacokinetics ; Oseltamivir/therapeutic use ; Viral Proteins/antagonists & inhibitors
Chemical Substances	Antiviral Agents ; Enzyme Inhibitors ; Viral Proteins ; Oseltamivir (20O93L6F9H) ; Neuraminidase (EC 3.2.1.18)
Language	English
Publishing date	2013-05-14
Publishing country	United Arab Emirates
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2234298-9
ISSN	2212-3989 ; 1871-5265
ISSN (online)	2212-3989
ISSN	1871-5265
DOI	10.2174/18715265112129990002
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5598: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Clinical and prognostic significance of CD27 and CD44 expression patterns in Egyptian pediatric patients with B-precursor acute lymphoblastic leukemia.

Abobakr, Asmaa / Osman, Randa A / Kamal, Mohamed A M / Abdelhameed, Sayed Abed / Ismail, Hagar H / Kamel, Mahmoud M / Alsharif, Khalaf F / Hamad, Nema R

Hematology, transfusion and cell therapy

2023

Abstract: Introduction: The expression pattern of CD27 and CD44 was found to correlate with the differentiation stages of B cell precursors, which were known to be involved in a variety of immunological responses.: Aim of the study: This study aimed to ... ...

Abstract	Introduction: The expression pattern of CD27 and CD44 was found to correlate with the differentiation stages of B cell precursors, which were known to be involved in a variety of immunological responses. Aim of the study: This study aimed to determine the biological significance of CD27 and CD44 expression in patients with B-precursor acute lymphoblastic leukemia (B-ALL), as well as their association with standard prognostic factors and therapeutic response. Patients and methods: This case-control study included 60 pediatric patients newly diagnosed with B-ALL and 30 pediatric controls. The patient CD27 and CD44 levels were measured using the Beckman Coulter Navios Flow Cytometer. Results: Most malignant cells (91.6 %) expressed CD44, but only 50 % of the patients had CD27 expressed. The positive CD 44 expression was associated with unfavorable prognostic markers, including a decrease.
Language	English
Publishing date	2023-12-06
Publishing country	Brazil
Document type	Journal Article
ISSN	2531-1387
ISSN (online)	2531-1387
DOI	10.1016/j.htct.2023.10.003
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: An Observational Study on the Pharmacokinetics of Oseltamivir in Lactating Influenza Patients.

Fodor, Eszter / Nagy, Regina N / Nógrádi, András / Toovey, Stephen / Kamal, Mohamed A / Vadász, Péter / Bencsik, Péter / Görbe, Anikó / Ferdinandy, Péter

Clinical pharmacology and therapeutics

2023 Volume 115, Issue 2, Page(s) 318–323

Abstract: Influenza infection may lead to serious complications in the postpartum period, therefore, oseltamivir treatment in these patients and their breastfed infants is of great importance. However, the pharmacokinetics of oseltamivir in postpartum lactating ... ...

Abstract	Influenza infection may lead to serious complications in the postpartum period, therefore, oseltamivir treatment in these patients and their breastfed infants is of great importance. However, the pharmacokinetics of oseltamivir in postpartum lactating women with acute influenza infection, and the consequent infant exposure to oseltamivir are still unknown, and these data would help in assessing risk and the need for dose adjustment in breastfed infants. Six lactating women with influenza-like symptoms, at a standard dose of 75 mg oral oseltamivir twice daily for 5 days, were recruited in this phase IV clinical study during the 2011/2012 H1N1 pandemic seasons. Breast milk/colostrum and venous blood samples were taken at multiple timepoints, maternal urine samples were obtained from total output within the 12-hour observational period following the seventh dose of oseltamivir. Oseltamivir phosphate (OP) reached a maximum 69.5 ± 29.4 ng/mL concentration in breast milk, higher than that found in the plasma, and showed elimination within ~ 8 hours. Oseltamivir carboxylate (active metabolite of OP) showed a lower, nearly steady-state concentration in breast milk during the observational period (maximum plasma concentration (C
MeSH term(s)	Infant ; Humans ; Female ; Oseltamivir ; Influenza, Human/drug therapy ; Antiviral Agents/pharmacokinetics ; Lactation ; Influenza A Virus, H1N1 Subtype
Chemical Substances	Oseltamivir (20O93L6F9H) ; Antiviral Agents
Language	English
Publishing date	2023-12-03
Publishing country	United States
Document type	Clinical Trial, Phase IV ; Observational Study ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	123793-7
ISSN	1532-6535 ; 0009-9236
ISSN (online)	1532-6535
ISSN	0009-9236
DOI	10.1002/cpt.3107
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 20: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Two versus three doses of COVID-19 vaccine and post-vaccination COVID-19 infection in hemodialysis patients.

Ahmed, Laila A / Mansour, Hayam H / Elshennawy, Salwa I / Ramadan, Marwa A A / Kamal, Mohamed A M / Mohamed, Soso S / Ali, Omaima Mohamed / Ibrhim, Amal H

Infection prevention in practice

2024 Volume 6, Issue 1, Page(s) 100338

Abstract: Background and aim: Patients with chronic kidney disease including those undergoing hemodialysis (HD) constitute a particularly challenging group regarding COVID-19 vaccination. The present study aimed to compare the rate of reinfection after two and ... ...

Abstract	Background and aim: Patients with chronic kidney disease including those undergoing hemodialysis (HD) constitute a particularly challenging group regarding COVID-19 vaccination. The present study aimed to compare the rate of reinfection after two and three doses of Sinopharm COVID-19 vaccine in HD patients. Patients and methods: The study included 80 HD patients who received three doses of Sinopharm COVID-19 vaccine. In addition, there were another 80 patients who received only two doses of the vaccine. Patients in the latter group were selected based on propensity matching score with 1:1 ratio. Patients were monitored for post-vaccination COVID-19 infection using PCR examination of nasopharyngeal swabs. Patients were also monitored for post-vaccination complications including general complaints (headache, fever, fatigue), injection site complaints (arm pain, swelling, itching, rash), musculoskeletal complaints (muscle spasm or pain, joint pain) and others. All patients were followed for six months. Results: The present study included 80 patients submitted to COVID-19 vaccination with two doses of Sinopharm vaccine (GI) and other 80 patients who received three doses of the same vaccine (GII). At the end of follow up, 11 patients (13.8 %) in GI caught COVID-19 infection. In contrast, no patient in GII had infection ( Conclusions: A three dose regime of Sinopharm COVID-19 vaccine associated with significantly lower rate of reinfection COVID-19 infection in HD patients. Infected patients had significantly lower BMI, higher frequency of HCV and higher ferritin levels.
Language	English
Publishing date	2024-01-10
Publishing country	England
Document type	Journal Article
ISSN	2590-0889
ISSN (online)	2590-0889
DOI	10.1016/j.infpip.2024.100338
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Modeling the Effect of Hydrophobicity on the Passive Permeation of Solutes across a Bacterial Model Membrane.

Sousa, Carla F / Kamal, Mohamed A M / Richter, Robert / Elamaldeniya, Kalanika / Hartmann, Rolf W / Empting, Martin / Lehr, Claus-Michael / Kalinina, Olga V

Journal of chemical information and modeling

2022 Volume 62, Issue 20, Page(s) 5023–5033

Abstract: Passive diffusion across biomembranes is an important mechanism of permeation for multiple drugs, including antibiotics. However, this process is frequently neglected while studying drug uptake and, in our view, warrants further investigation. Here, we ... ...

Abstract	Passive diffusion across biomembranes is an important mechanism of permeation for multiple drugs, including antibiotics. However, this process is frequently neglected while studying drug uptake and, in our view, warrants further investigation. Here, we apply molecular dynamics simulations to investigate the impact of changes in molecular hydrophobicity on the permeability of a series of inhibitors of the quorum sensing of Pseudomonas aeruginosa, previously discovered by us, across a membrane model. Overall, we show that permeation across this membrane model does not correlate with the molecule's hydrophobicity. We demonstrate that using a simple model for permeation, based on the difference between the maximum and minimum of the free energy profile, outperforms the inhomogeneous solubility-diffusion model, yielding a permeability ranking that better agrees with the experimental results, especially for hydrophobic permeants. The calculated differences in permeability could not explain differences in in bacterio activity. Nevertheless, substantial differences in molecular orientation along the permeation pathway correlate with the in bacterio activity, emphasizing the importance of analyzing, at an atomistic level, the permeation pathway of these solutes.
MeSH term(s)	Solutions ; Diffusion ; Molecular Dynamics Simulation ; Hydrophobic and Hydrophilic Interactions ; Anti-Bacterial Agents
Chemical Substances	Solutions ; Anti-Bacterial Agents
Language	English
Publishing date	2022-10-10
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	190019-5
ISSN	1549-960X ; 0095-2338
ISSN (online)	1549-960X
ISSN	0095-2338
DOI	10.1021/acs.jcim.2c00767
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1230: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Pharmacokinetics of Subcutaneous Dupilumab Injection With an Autoinjector Device or Prefilled Syringe.

Cohen, Yehuda Z / Zhang, Xiaojia / Xia, Binfeng / Kosloski, Matthew P / Kamal, Mohamed A / Davis, John D / Kanamaluru, Vanaja / Xu, Christine

Clinical pharmacology in drug development

2022 Volume 11, Issue 5, Page(s) 675–681

Abstract: Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, has demonstrated efficacy and an acceptable safety profile in adult and pediatric patients with moderate-to-severe atopic dermatitis (AD) and other type 2 inflammatory diseases. ...

Abstract	Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, has demonstrated efficacy and an acceptable safety profile in adult and pediatric patients with moderate-to-severe atopic dermatitis (AD) and other type 2 inflammatory diseases. Dupilumab is available in 200- and 300-mg strengths as a prefilled syringe with a needle shield (PFS-S), and more recently as an autoinjector (AI) device. This study was designed to assess the pharmacokinetic (PK) comparability of a single subcutaneous (SC) dose of dupilumab 200 mg, delivered by 2 different devices, AI (test) versus PFS-S (reference). A total of 130 healthy male and female participants were enrolled in this phase 1 parallel design study, with 128 evaluable for PK. Following dupilumab 200-mg SC injection, dupilumab exposure in serum was similar for both AI and PFS-S. The geometric mean ratios of PK parameters with 90% confidence intervals were 1.08 (0.97-1.21) for maximum serum concentration (C
MeSH term(s)	Adult ; Antibodies, Monoclonal, Humanized/pharmacokinetics ; Child ; Female ; Humans ; Injections, Subcutaneous ; Male ; Syringes ; Therapeutic Equivalency
Chemical Substances	Antibodies, Monoclonal, Humanized ; dupilumab (420K487FSG)
Language	English
Publishing date	2022-03-12
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2649010-9
ISSN	2160-7648 ; 2160-763X
ISSN (online)	2160-7648
ISSN	2160-763X
DOI	10.1002/cpdd.1073
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article: Promoter methylation might shift the balance of Galectin-3 & 12 expression in

Assem, Magda / El-Araby, Rady E / Al-Karmalawy, Ahmed A / Nabil, Reem / Kamal, Mohamed A M / Belal, Amany / Ghamry, Heba I / Abourehab, Mohammed A S / Ghoneim, Mohammed M / Alshahrani, Mohammad Y / El Leithy, Asmaa A

Frontiers in genetics

2023 Volume 14, Page(s) 1122864

Abstract: Acute myeloid leukemia (AML) was reported as the most common type of leukemia among adults. Galectins constitute a family of galactose-binding proteins reported to play a critical role in many malignancies including AML. Galectin-3 and -12 are members of ...

Abstract	Acute myeloid leukemia (AML) was reported as the most common type of leukemia among adults. Galectins constitute a family of galactose-binding proteins reported to play a critical role in many malignancies including AML. Galectin-3 and -12 are members of the mammalian galectin family. To understand the contribution of galectin-3 and -12 promoter methylation to their expression, we performed bisulfite methylation-specific (MSP)-PCR and bisulfite genomic sequencing (BGS) of primary leukemic cells in patients with
Language	English
Publishing date	2023-02-13
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2606823-0
ISSN	1664-8021
ISSN	1664-8021
DOI	10.3389/fgene.2023.1122864
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trials.

Kosloski, Matthew P / Kalliolias, George D / Xu, Christine R / Harel, Sivan / Lai, Ching-Ha / Zheng, Wenjun / Davis, John D / Kamal, Mohamed A

Clinical and translational science

2021 Volume 15, Issue 2, Page(s) 384–395

Abstract: Itepekimab is a monoclonal antibody that targets interleukin (IL-33) and has been shown to reduce airway inflammation and associated tissue damage in preclinical studies. We assessed the safety, tolerability, pharmacokinetics (PKs), and pharmacodynamic ... ...

Abstract	Itepekimab is a monoclonal antibody that targets interleukin (IL-33) and has been shown to reduce airway inflammation and associated tissue damage in preclinical studies. We assessed the safety, tolerability, pharmacokinetics (PKs), and pharmacodynamic profiles of single-ascending and multiple-ascending doses of itepekimab in two randomized, double-blind, placebo-controlled phase I studies. Healthy adults (N = 40) were randomized to the single-dose study and patients with moderate asthma (N = 23) to the multiple-dose study. Itepekimab was administered intravenously (0.3, 1, 3, or 10 mg/kg infusion) or subcutaneously (150 mg) in the single-dose study and subcutaneously (75 or 150 mg weekly for 4 weeks) in the multiple-dose study. Itepekimab exhibited linear PKs across studies and dose-proportional increases in mean maximum concentration in serum and area under the concentration-time curve following single intravenous or multiple subcutaneous doses. Itepekimab demonstrated mean subcutaneous bioavailability of 59-73% and a long terminal half-life (30.0-31.6 days). IL-33 concentrations in most healthy participants and patients with asthma were undetectable at baseline. Following administration of itepekimab in both studies, total IL-33 concentrations increased and blood eosinophils decreased, both with durable effect. Itepekimab was well-tolerated in both studies with no detection of treatment-emergent anti-drug antibody responses.
MeSH term(s)	Administration, Intravenous ; Adult ; Antibodies, Monoclonal/pharmacokinetics ; Antibodies, Monoclonal, Humanized ; Asthma/chemically induced ; Asthma/drug therapy ; Dose-Response Relationship, Drug ; Double-Blind Method ; Healthy Volunteers ; Humans
Chemical Substances	Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; itepekimab (WV9KZ9PS1A)
Language	English
Publishing date	2021-09-29
Publishing country	United States
Document type	Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	2433157-0
ISSN	1752-8062 ; 1752-8054
ISSN (online)	1752-8062
ISSN	1752-8054
DOI	10.1111/cts.13157
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Base and Covariate Population Pharmacokinetic Analyses of Dupilumab in Adolescents and Children ≥6 to <12 Years of Age Using Phase 3 Data.

Kovalenko, Pavel / Kamal, Mohamed A / Davis, John D / Huniti, Nidal / Xu, Christine / Bansal, Ashish / Shumel, Brad / DiCioccio, A Thomas

Clinical pharmacology in drug development

2021 Volume 10, Issue 11, Page(s) 1345–1357

Abstract: Population pharmacokinetic (PK) base and covariate analyses were conducted using data from adolescents with moderate-to-severe atopic dermatitis (AD) and children ≥6 to <12 years of age with severe AD. Two phase 3 studies were analyzed (165 adolescents ... ...

Abstract	Population pharmacokinetic (PK) base and covariate analyses were conducted using data from adolescents with moderate-to-severe atopic dermatitis (AD) and children ≥6 to <12 years of age with severe AD. Two phase 3 studies were analyzed (165 adolescents and 241 children on active treatment). A 2-compartment model with linear and Michaelis-Menten elimination and 3 transit compartments describing lag time in absorption was utilized. Weight, albumin, body mass index, and Eczema Area and Severity Index score were statistically significant covariates in at least 1 of the age populations. Only body weight had a consequential effect on central volume. Although an absorption rate and target-mediated clearance somewhat decreased with age, no dose adjustment was needed in addition to the adjustment for weight already implemented in the phase 3 studies. Otherwise, population PK parameters and covariates were similar across the 2 pediatric subpopulations and in adults. No allometric changes in elimination rate and beta half-life were observed with weight. Parameterization of models in terms of rates was a useful alternative to parameterization in terms of clearances, allowing for an absence of repeated covariates and preventing overparameterization. The model adequately described dupilumab pharmacokinetics in the pediatric populations.
MeSH term(s)	Antibodies, Monoclonal, Humanized/pharmacokinetics ; Child ; Clinical Trials, Phase III as Topic ; Dermatitis, Atopic/drug therapy ; Female ; Humans ; Male
Chemical Substances	Antibodies, Monoclonal, Humanized ; dupilumab (420K487FSG)
Language	English
Publishing date	2021-06-23
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2649010-9
ISSN	2160-7648 ; 2160-763X
ISSN (online)	2160-7648
ISSN	2160-763X
DOI	10.1002/cpdd.986
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito